Aimmune Therapeutics Inc (NASDAQ:AIMT) CFO Eric Bjerkholt Acquires 1,550 Shares

Aimmune Therapeutics Inc (NASDAQ:AIMT) CFO Eric Bjerkholt acquired 1,550 shares of the stock in a transaction that occurred on Wednesday, September 18th. The stock was purchased at an average price of $22.57 per share, for a total transaction of $34,983.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

AIMT opened at $22.66 on Monday. The company has a debt-to-equity ratio of 0.24, a current ratio of 5.80 and a quick ratio of 5.80. The company’s 50 day simple moving average is $20.71 and its two-hundred day simple moving average is $20.77. Aimmune Therapeutics Inc has a 1-year low of $16.95 and a 1-year high of $36.12.

Aimmune Therapeutics (NASDAQ:AIMT) last released its earnings results on Thursday, August 8th. The biotechnology company reported ($1.01) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.93) by ($0.08). During the same period last year, the firm earned ($0.91) EPS. Equities research analysts anticipate that Aimmune Therapeutics Inc will post -4 EPS for the current year.

Several equities research analysts recently issued reports on AIMT shares. Roth Capital started coverage on Aimmune Therapeutics in a report on Friday, July 12th. They issued a “buy” rating and a $45.00 price objective on the stock. BidaskClub cut Aimmune Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, August 24th. Wedbush reiterated an “outperform” rating and issued a $79.00 price objective on shares of Aimmune Therapeutics in a report on Monday, September 16th. Stifel Nicolaus upgraded Aimmune Therapeutics to a “positive” rating in a report on Monday, September 16th. Finally, Zacks Investment Research cut Aimmune Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, September 5th. One research analyst has rated the stock with a sell rating, two have given a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Aimmune Therapeutics currently has a consensus rating of “Buy” and an average target price of $42.13.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Aperio Group LLC purchased a new position in Aimmune Therapeutics in the 2nd quarter worth approximately $76,000. Botty Investors LLC purchased a new position in Aimmune Therapeutics in the 1st quarter worth approximately $2,505,000. DekaBank Deutsche Girozentrale lifted its stake in Aimmune Therapeutics by 21.8% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 15,100 shares of the biotechnology company’s stock worth $423,000 after purchasing an additional 2,700 shares in the last quarter. TD Asset Management Inc. lifted its stake in Aimmune Therapeutics by 5.7% in the 2nd quarter. TD Asset Management Inc. now owns 100,076 shares of the biotechnology company’s stock worth $2,084,000 after purchasing an additional 5,400 shares in the last quarter. Finally, GSA Capital Partners LLP purchased a new position in Aimmune Therapeutics in the 2nd quarter worth approximately $221,000. 78.06% of the stock is currently owned by institutional investors and hedge funds.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy.

Featured Article: Bond

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.